21Shares has recently filed a new application for a spot exchange-traded fund (ETF) focused on Injective (INJ) with the U.S. Securities and Exchange Commission. This submission, made on October 20, 2025, positions Injective among several altcoins vying for ETF approval. Currently, INJ is trading at $8.75 as the cryptocurrency market experiences a resurgence following recent lows, driven by a bullish sentiment around ETFs.
21Shares Submits Application for New Injective Spot ETF
The official X account for Injective announced the filing of the 21Shares INJ ETF with the SEC on Monday. The application reveals that the 21Shares Injective ETF aims to provide investors with direct exposure to INJ. Similar to other proposed listings, and following the recent launches of spot Bitcoin and Ethereum ETFs, this fund will hold physical INJ tokens in cold storage.
“This is a significant indicator of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress,” the Injective team posted on X.
Injective ranks among the top 100 cryptocurrencies, and its growth within the industry is underpinned by a strong appeal within sectors such as decentralized finance (DeFi) and real-world assets. Recently, the Layer 1 project held its inaugural Injective Council meeting, demonstrating the growing presence and adoption of the platform, which is bolstered by industry leaders supporting its strategic roadmap. Key objectives include the native Ethereum virtual machine, digital asset treasury, INJ ETFs, and pre-IPO markets.
Prominent partners include Google Cloud, T-Mobile, Deutsche Telekom, YZi Labs, Galaxy Digital, and BitGo. Earlier this year, Canary Capital also submitted an application for an INJ ETF in July.
Injective operates as a high-performance Layer 1 blockchain designed for decentralized financial services. The platform boasts the capability to process over 25,000 transactions per second and utilizes its native token, INJ, to secure the network through a Delegated Proof-of-Stake (DPoS) consensus mechanism. It addresses infrastructure challenges, such as fragmented liquidity and slow transaction finality, by integrating exchange primitives with CosmWasm-based composability, while Comet BFT (formerly Tendermint BFT) ensures rapid finality.
INJ Price Outlook Amid ETF Approval Buzz
As reported, INJ is trading around $8.75 amid broader cryptocurrency volatility. Although the token’s price has not surged in light of the ETF news, enthusiasm remains high in the market. Optimistic predictions are primarily fueled by anticipation that the SEC is poised to approve several crypto ETFs, helping to alleviate current downward market pressures and allowing bullish momentum to take over.
Nonetheless, the price of Injective has declined from a peak of nearly $35 in December 2024, well below its all-time high of $52.75 achieved in March 2024. However, bulls are striving to stay above the $8 mark following a dip to approximately $7.80 after the downturn on October 17, 2025. Prior to that, INJ showed resilience, bouncing back from a low of $6.90 in April.
In addition to the ETF-driven sentiment, investments in treasury assets, such as Pineapple Financial’s recent $100 million movement, are also supporting bullish trends.
Meet William, a proud Bethel University alumnus with a fervent passion for lifestyle and culture topics. His keen interest doesn’t stop there; he’s also deeply engrossed in current events of all kinds. William dedicates himself wholeheartedly to this site, thriving on the collaborative energy he shares with Suzanne, his long-standing partner in crime.
Having navigated their university courses side by side for years, their teamwork on the site is nothing short of dynamic. Together, they bring a unique blend of insights, proving that two heads are indeed better than one in delivering compelling content.
